Clinical trials: Obesity, Overweight
Weight Loss
Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects
The purpose of the study is to evaluate the effect on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight > 75 Kg/m2 being administered with a 3 g/day…
- Trial name
- POSO (NCT04375696)
- Testing
- Polyglucosamine L112
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Tachycardia Atrial, Atrial Fibrillation
BIO|STREAM.ICM Obesity
The aim of the submodule study is to assess whether a high BMI may influence the sensing performance and the sECG quality of the BIOMONITOR.
- Conditions
- Tachycardia Atrial, Atrial Fibrillation, Syncope, Bradycardia
- Trial name
- NCT04198220
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Biotronik SE & Co. KG
Obesity
Endostapler Gastric Bypass Study
The goal of this prospective, post-market study is to evaluate safety and efficacy of the AEON™ Endostapler when used in laparoscopic Roux-en-Y gastric bypass surgery.
- Trial name
- NCT04712526
- Testing
- AEON Endostapler
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lexington Medical Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Obesity, Morbid
The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol
This is a five-year, single arm, multi-center trial to evaluate the long-term safety and efficacy of the Maestro Rechargeable System in treating obesity. The study will include an observational arm and a randomized sub-study.
- Trial name
- ReNEW (NCT03145636)
- Testing
- vBloc Maestro Rechargeable System, vBloc Achieve Weight Management Program, Control Weight Management (CWM) program
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- ReShape Lifesciences
Pro-opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type…
- Trial name
- NCT02896192
- Testing
- Setmelanotide
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Obesity
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.
- Trial name
- NCT00261911
- Testing
- sibutramine
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Abbott
Obesity and Obesity-related Medical Conditions, Weight Loss
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
The objective of this study is to assess the long term weight loss and weight loss journey of patients who received an Endoscopic Sleeve Gastroplasty (ESG) 5 or more years prior to enrollment.
- Trial name
- LIGHT (NCT06894498)
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 34 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Metabolism and Nutrition Disorder, Obesity
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with…
- Trial name
- NCT03015207
- Testing
- NNC0194-0499
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorders, Overweight or Obesity
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body.
- Trial name
- NCT03574584
- Testing
- NNC0165-1562, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Oxidative Stress
Clinical Trial to Investigate the Efficacy and Safety of LN-OS-22 on Oxidative Stress and Systemic Inflammation in Overweight and Obese Population.
The present clinical investigation has been proposed to further substantiate the evidence of the antioxidant and anti-inflammatory activity of the extract in the healthy adult population with BMI ranging from ≥25.0 kg/m2 and ≤…
- Trial name
- NCT05404217
- Testing
- LN-OS-22, Maltodextrin
- Where
- 3 sites in India
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Dyslipidemia, Sleep Apnea Syndrome
Effect of Fenofibrate on Sleep Apnea Syndrome
Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.
- Conditions
- Dyslipidemia, Sleep Apnea Syndrome, Overweight, Obesity
- Trial name
- NCT00816829
- Testing
- Fenofibrate
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Solvay Pharmaceuticals
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Obesity
A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of a single intravenous (through a vein) dose of trodusquemine (MSI-1436) in obese, type 2 diabetics.
- Trial name
- NCT00606112
- Testing
- Trodusquemine (MSI-1436)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Genaera Corporation
Obesity
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
The purpose of this study is to retrospectively and systematically review records of overweight and obese Medifast Weight Control Center (MWCC) members who have been assigned to the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for…
- Trial name
- NCT02150837
- Testing
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Adolescent Obesity, Obesity in Adolescence
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in…
- Conditions
- Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
- Trial name
- NCT03922945
- Testing
- VI-0521 oral capsule, Lifestyle Modification
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- VIVUS LLC
Obesity
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
- Trial name
- RESOLVE-2 (NCT07220629)
- Testing
- NT-0796
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Rezera (formerly NodThera Limited)
Obesity
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
- Trial name
- NCT02243202
- Testing
- Canagliflozin, Phentermine
- Where
- 17 sites in United States
- Volunteers
- 335 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.